Cited by 1,008T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 41 of the 44 references it cites were found in a registry or an index.

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Open access

Sutmuller, Roger P.M., van Duivenvoorde, Leonie M., van Elsas, Andrea, Schumacher, Ton N.M., Wildenberg, Manon E., Allison, James P., Toes, Rene E.M., Offringa, Rienk, Melief, Cornelis J.M.·2001·The Journal of Experimental Medicine

DOI 10.1084/jem.194.6.823PMC PMC2195955

Open this paper in CoChat — free account

Abstract

Therapeutic efficacy of a tumor cell–based vaccine against experimental B16 melanoma requires the disruption of either of two immunoregulatory mechanisms that control autoreactive T cell responses: the cytotoxic T lymphocyte–associated antigen (CTLA)-4 pathway or the CD25+ regulatory T (Treg) cells. Combination of CTLA-4 blockade and depletion of CD25+ Treg cells results in maximal tumor rejection. Efficacy of the antitumor therapy correlates with the extent of autoimmune skin depigmentation as well as with the frequency of tyrosinase-related protein 2180–188–specific CTLs detected in the periphery. Furthermore, tumor rejection is dependent on the CD8+ T cell subset. Our data demonstrate that the CTL response against melanoma antigens is an important component of the therapeutic antitumor response and that the reactivity of these CTLs can be augmented through interference with immunoregulatory mechanisms. The synergism in the effects of CTLA-4 blockade and depletion of CD25+ Treg cells indicates that CD25+ Treg cells and CTLA-4 signaling represent two alternative pathways for suppression of autoreactive T cell immunity. Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.194.6.823

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells
Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“H-2K b tetramers were produced as described previously (20, 21) and stored frozen in Tris-buffered saline/16% glycerol/0.”
Method
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 2×
“Anderson Cancer Center, Houston, TX), GM-CSF‐producing B16 cell lines BL6/GM-E, BL6/GM18 (18), B16/B7.1 (18), 9H10 ( 19 ), and PC61 (American Type Culture Collection) were cultured in Iscove’s IMDM (BioWhittaker) supplemented with 1 U/ml penicillin, 1 � g/ml streptomycin, 2 � M L -glutamine, 20 � M � -mercaptoethanol…”
MethodSelf-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,566

Flagged first, then by citations

Show all 44 references

3 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Items 701–800 of 1,000

Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and IL‐22 binding protein
Janakiram, N. B., Mohammed, A., Bryant, T., Brewer, M. F., Biddick, L., Lightfoot, S. A., Lang, M. L., & Rao, C. V. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22168 · Cited by 16
Mechanisms of Cyclic Nucleotide Phosphodiesterases in Modulating T Cell Responses in Murine Graft-versus-Host Disease
Weber, M., Lupp, C., Stein, P., Kreft, A., Bopp, T., Wehler, T. C., Schmitt, E., Schild, H., & Radsak, M. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058110 · Cited by 16
Synergistic effects of CTLA‐4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo
Suárez, N., Alfaro, C., Dubrot, J., Palazón, A., Bolaños, E., Erro, L., Hervás‐Stubbs, S., Martínez‐Forero, I., Morales‐Kastresana, A., Martín‐Algarra, S., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25681 · Cited by 16
Development of Novel Immune Interventions for Prostate Cancer
Agarwal, N., Padmanabh, S., & Vogelzang, N. J. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.01.012 · Cited by 16
A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti‐tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice
Takeuchi, A., Eto, M., Yamada, H., Tatsugami, K., Naito, S., & Yoshikai, Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.26009 · Cited by 16
Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary location
Kakinuma, T., Nadiminti, H., Lonsdorf, A. S., Murakami, T., Perez, B. A., Kobayashi, H., Finkelstein, S. E., Pothiawala, G., Belkaid, Y., & Hwang, S. T. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0253-4 · Cited by 16
Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Candolfi, M., Kroeger, K. M., Xiong, W., Liu, C., Puntel, M., Yagiz, K., Muhammad, A. G., Mineharu, Y., Foulad, D. S., Wibowo, M., et al. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011797378689 · Cited by 18
Novel agents in development for the treatment of melanoma
Tarhini, A. A., & Agarwala, S. S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.7.885 · Cited by 16
Peptide Vaccines Against Cancer
Berzofsky, J. A., Oh, S., & Terabe, M. (2005) · Cancer treatment and research · doi:10.1007/0-387-27545-2_5 · Cited by 16
Tumor–associated antigens identified by mRNA expression profiling as tumor rejection epitopes
Andersen, M. L. M., Rühwald, M., Thorn, M., Pedersen, A. E., Mathiassen, S., Buus, S., & Claësson, M. H. (2003) · Journal of Immune Based Therapies and Vaccines · doi:10.1186/1476-8518-1-1 · Cited by 16
PRACTICAL ASPECTS OF POULTRY VACCINATION
Schijns, V. E. C. J., SHARMA, J. M., & Tarpey, I. (2008) · Elsevier eBooks · doi:10.1016/b978-012370634-8.50023-8 · Cited by 16
CTLA-4 Engagement and Regulatory CD4+CD25+ T Cells Independently Control CD8+-Mediated Responses under Costimulation Blockade
Coenen, J. J. A., Koenen, H. J. P. M., van Rijssen, E., Boon, L., Joosten, I., & Hilbrands, L. B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5240 · Cited by 16
CD4+CD25+ T regulatory cells do not transfer oral tolerance to peanut allergens in a mouse model of peanut allergy
Rezende, M., Hassing, I., Bol-Schoenmakers, M., Bleumink, R., Boon, L., van Bilsen, J. V., & Pieters, R. (2011) · Clinical and Experimental Allergy · doi:10.1111/j.1365-2222.2010.03662.x · Cited by 15
Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer
Chentoufi, A. A., Nesburn, A. B., & BenMohamed, L. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0049-2 · Cited by 15
The Ubiquitin E3 Ligase Cbl-b in T Cells Tolerance and Tumor Immunity
Loeser, S., & Penninger, J. M. (2007) · Cell Cycle · doi:10.4161/cc.6.20.4797 · Cited by 15
‘Survival gene’ Bcl-xl potentiates DNA-raised antitumor immunity
Kim, J. H., Chen, J., Majumder, N., Lin, H., Falo, L. D., & You, Z. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302584 · Cited by 15
The immunomodulatory effects of regulatory T cells: implications for immune regulation in the skin
Birch, K. E., Vukmanovic‐Stejic, M., Reed, J. R., Akbar, A. N., & Rustin, M. H. A. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06476.x · Cited by 15
General Principles of Tumor Immunotherapy
Kaufman, H. L., & Wolchok, J. D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8 · Cited by 15
The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy
Ahmadpour, S., Habibi, M. A., Ghazi, F. S., Molazadeh, M., Pashaie, M. R., & Mohammadpour, Y. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100823 · Cited by 14
Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma
Weng, J., Neelapu, S. S., Woo, A. F., & Kwak, L. W. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_70 · Cited by 14
Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice
Gritzapis, A. D., Voutsas, I. F., & Baxevanis, C. N. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1113-4 · Cited by 14
Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report
Bota, D. A., Alexandru, D., Pretto, C. M., Hofman, F. M., Chen, T. C., Fu, B. D., Carrillo, J., Schijns, V. E. C. J., & Stathopoulos, A. (2015) · The Permanente Journal · doi:10.7812/tpp/14-042 · Cited by 14
Using monoclonal antibodies to stimulate antitumor cellular immunity
Durrant, L. G., Pudney, V. A., & Spendlove, I. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.33 · Cited by 14
Distribution of Regulatory T-Cells and Other Phenotypes of T-Cells in Tumors and Regional Lymph Nodes of Colorectal Cancer Patients
Kazama, K., OTAKE, J., Satoyoshi, T., Shiozawa, M., Sugano, N., Sato, S., Atsumi, Y., Kano, K., Murakawa, M., Maezawa, Y., et al. (2020) · In Vivo · doi:10.21873/invivo.11848 · Cited by 15
Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice
Saha, A., & Chatterjee, S. K. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.02.010 · Cited by 14
Novel tumour antigens and the development of optimal vaccine design
Brentville, V. A., Atabani, S., Cook, K., & Durrant, L. G. (2018) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135518768769 · Cited by 14
B7-Deficient Autoreactive T Cells Are Highly Susceptible to Suppression by CD4+CD25+ Regulatory T Cells
May, K. F., Chang, X., Zhang, H., Lute, K. D., Zhou, P., Kocak, E., Zheng, P., & Liu, Y. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1542 · Cited by 14
Trends in Cancer Immunotherapy
Murphy, J. F. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s4795 · Cited by 15
Effect of cytotoxic T-lymphocyte-associated protein 4 on CD4+CD25+ regulatory T cells in murine Schistosomiasis japonica
Tang, C., Lei, J., Guan, F., Li, Y., Liu, R., Grevelding, C. G., Jiang, M.-S., & Dong, H. (2013) · Experimental Parasitology · doi:10.1016/j.exppara.2013.11.001 · Cited by 13
Immunotherapy of Melanoma
Snyder, A., Zamarin, D., & Wolchok, J. D. (2015) · Progress in tumor research · doi:10.1159/000436998 · Cited by 15
Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation
Horkheimer, I., Quigley, M. M., Zhu, J., Huang, X., Chao, N. J. A., & Yang, Y. (2009) · Blood · doi:10.1182/blood-2008-05-155150 · Cited by 13
Synergistic and Additive Effects of Cimetidine and Levamisole on Cellular Immune Responses to Hepatitis B virus DNA Vaccine in Mice
Niu, X., Yang, Y., & Wang, J. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12018 · Cited by 13
Harnessing Immune Checkpoints for Cancer Therapy
Vinay, D. S., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0168 · Cited by 14
Resistance to Apoptosis and Expansion of Regulatory T Cells in Relation to the Detection of Circulating Tumor Cells in Patients with Metastatic Epithelial Cancer
Stanzer, S., Dandachi, N., Balić, M., Resel, M., Samonigg, H., & Bauernhofer, T. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9139-2 · Cited by 13
Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies
Essand, M. (2005) · Acta Oncologica · doi:10.1080/02841860510007477 · Cited by 13
Spleen Plays an Important Role in Maintaining Tolerance After Removal of the Vascularized Heart Graft
Chosa, E., Hara, M., Watanabe, A., Matsuzaki, Y., Nakamura, K., Hamano, K., Wood, K. J., & Onitsuka, T. (2007) · Transplantation · doi:10.1097/01.tp.0000259928.16003.aa · Cited by 13
Immunogenic, but Not Steady-State, Antigen Presentation Permits Regulatory T-Cells To Control CD8+ T-Cell Effector Differentiation by IL-2 Modulation
McNally, A., McNally, M., Galea, R. C., Thomas, R., & Steptoe, R. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085455 · Cited by 13
Effect of Peripheral Blood Lymphocytes on Prognosis of Multiple Cancers
Zhang, X., & Jing, J. (2023) · Cancer Control · doi:10.1177/10732748231202921 · Cited by 12
Immune profiling and cancer post transplantation
Hope, C. M. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i1.41 · Cited by 12
Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic cell immunotherapy and combinatorial regimens
Milano, F., & Krishnadath, K. K. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.07.006 · Cited by 12
Antigen Choice Determines Vaccine-Induced Generation of Immunogenic versus Tolerogenic Dendritic Cells That Are Marked by Differential Expression of Pancreatic Enzymes
Farkas, A. M., Marvel, D., & Finn, O. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203321 · Cited by 12
Costimulation in Lymphomas and Cancers
Mir, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802585-7.00005-4 · Cited by 12
From 'perfect mix' to 'potion magique' — regulatory T cells and anti-inflammatory cytokines as adjuvant targets
Bayry, J., Flower, D. R., Tough, D. F., & Kaveri, S. V. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1681-c1 · Cited by 12
Clinical-scale single-step CD4+ and CD8+ cell depletion for donor innate lymphocyte infusion (DILI)
Smetak, M., Kimmel, B., Birkmann, J., Schaefer‐Eckart, K., Einsele, H., Wilhelm, M., & Kunzmann, V. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705942 · Cited by 12
T Cell Tolerance to Tumors and Cancer Immunotherapy
Shafer-Weaver, K., Anderson, M. J. M., Malyguine, A. M., & Hurwitz, A. A. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72005-0_38 · Cited by 12
Modulation of aged murine T lymphocytes in vivo by DPV576-C, a nanodiamond- and nanoplatinum-coated material.
Ghoneum, M. H., Ghoneum, A., Tolentino, L., & Gimzewski, J. K. (2010) · PubMed · Cited by 12
Cell-based therapy approaches using dying cells: from tumour immunotherapy to transplantation tolerance induction
Saas, P., Tiberghien, P., & Bittencourt, M. D. C. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.3.249 · Cited by 12
Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010)
Ridolfi, L., & Ridolfi, R. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.11 · Cited by 11
Regulatory T cells in B‐cell‐deficient and wild‐type mice differ functionally and in expression of cell surface markers
Ellis, J. S., & Braley‐Mullen, H. (2014) · Immunology · doi:10.1111/imm.12410 · Cited by 11
Different mechanisms regulate CD4+ T cell independent induction of oral and nasal tolerance of CD8+ T cells
van den Berg, H., Greuter, M., Kraal, G., & den Haan, J. M. M. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.01.012 · Cited by 11
Lithraea caustic (Litre) Extract Promotes an Antitumor Response Against B16 Melanoma
Robles-Planells, C., Michelson, S., Mena, J., Escrig, D., Rojas, J. L., Sánchez-Guerrero, G., Hernández, R., Barrera‐Avalos, C., Rojo, L. E., Sauma, D., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01201 · Cited by 11
The immune system endogenous anticancer mechanism
Bonorino, C. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e547 · Cited by 11
Polymyxin B increases the depletion of T regulatory cell induced by purinergic agonist
Cappelli, C., López, X., Labra, Y., Montoya, M., Fernández, R., Imarai, M., Rojas, J. L., Miranda, D., Escobar, A. F., & Acuña‐Castillo, C. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.10.006 · Cited by 11
Therapeutic Vaccine for Lymphoma
Lee, S., Neelapu, S. S., & Kwak, L. W. (2007) · Yonsei Medical Journal · doi:10.3349/ymj.2007.48.1.1 · Cited by 11
Mechanisms of the self/non-self-survey in the defense against cancer: Potential for chemoprevention?
Sharma, R. A., & Browning, M. J. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.12.009 · Cited by 11
Immunotherapeutic Strategies: The Melanoma Example
Jorritsma, A., Schumacher, T. N., & Haanen, J. B. A. G. (2009) · Immunotherapy · doi:10.2217/imt.09.20 · Cited by 10
Self-citation
Searching for Peptide Inhibitors of T Regulatory Cell Activity by Targeting Specific Domains of FOXP3 Transcription Factor
Lozano, T., Casares, N., Martín-Otal, C., Anega, B., Gorraiz, M., Parker, J., Ruiz, M., Belsúe, V., Pineda‐Lucena, A., Oyarzábal, J., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9020197 · Cited by 10
DC‐induced CD8+ T‐cell response is inhibited by MHC class II‐dependent DX5+CD4+ Treg
Han, W. G. H., Schuurhuis, D. H., Fu, N., Camps, M. G. M., van Duivenvoorde, L. M., Louis‐Plence, P., Franken, K. L. M. C., Huizinga, T. W. J., Melief, C. J. M., Toes, R. E. M., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200838842 · Cited by 10
Self-citation
Detection of Suppressor T Lymphocytes and Estimation of Their Frequency in Limiting Dilution Assays by Generalized Linear Regression Modeling
Bonnefoix, T., Bonnefoix, P., Mi, J., Lawrence, J., Sotto, J., & Leroux, D. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.2884 · Cited by 10
Combination of Adoptive Cell Transfer and Antibody Injection Can Eradicate Established Tumors in Mice–Anin vivostudy using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb–
Watanabe, A., Hara, M., Chosa, E., Nakamura, K., Sekiya, R., Shimizu, T. M., & Onitsuka, T. (2009) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923970903222355 · Cited by 9
Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer
Ding, Y., Wang, Z., Zhou, F.-M., Chen, C., & Qin, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.987302 · Cited by 9
Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy
Liu, H., Pedros, C., Kong, K., Canonigo-Balancio, A. J., Xue, W., & Altman, A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002792 · Cited by 9
Antagonists of Tumor-Specific Immunity: Tumor-Induced Immune Suppression and Host Genes that Co-opt the Anti-Tumor Immune Response
Ostrand‐Rosenberg, S., Sinha, P., Danna, E. A., Miller, S., Davis, C., & Dissanayake, S. K. (2004) · Breast Disease · doi:10.3233/bd-2004-20113 · Cited by 9
Tumor Microenvironment
Walser, T. C., Yanagawa, J., Garon, E. B., Lee, J. M., & Dubinett, S. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-524-8_2 · Cited by 9
Tumor resistance to CD8+ T cell-based therapeutic vaccination
Huang, Y., Shah, S., & Qiao, L. (2007) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-007-0029-3 · Cited by 9
Regulation of CTL responses to MHC‐restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC–mGM‐CSF
Ahmad, M., Rees, R. C., McArdle, S., Li, G., Mian, S., Entwisle, C., Loudon, P. T., & Ali, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.20976 · Cited by 9
Control of immune responses by immunoregulatory T cells
Rudge, G., Gleeson, P. A., & van Driel, I. R. (2006) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-006-0045-8 · Cited by 9
Design, optimisation and standardisation of a high‐dimensional spectral flow cytometry workflow assessing T‐cell immunophenotype in patients with melanoma
Edwards, J. M., Andrews, M. C., Burridge, H., Smith, R., Owens, C., Edinger, M., Pilkington, K. R., Desfrançois, J., Shackleton, M. J., Senthi, S., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1466 · Cited by 8
A Functional Food Inhibits Azoxymethane/Dextran Sulfate Sodium-Induced Inflammatory Colorectal Cancer in Mice
Zhang, J., Chen, Z., Lu, Y., Tu, D., Zou, F., Lin, S., Yu, W., Miao, M., & Shi, H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s283465 · Cited by 8
Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime–boost vaccination against cancer
Dai, M., Vassaux, G., Xu, M., You, R.-I., Hsieh, Y.-F., Ouisse, L., Lo, K.-Y., Sytwu, H., & Chao, T.-Y. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.09.001 · Cited by 8
Therapeutic options in cutaneous melanoma: latest developments
Amaria, R. N., Lewis, K. D., & Gonzalez, R. C. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011415308 · Cited by 9
Physiological organization of immune response based on the homeostatic mechanism of matrix reprogramming: Implication in tumor and biotechnology
Malyshev, I. Y., Manukhina, E. B., & Malyshev, Y. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.03.019 · Cited by 8
The T h POK transcription factor differentially affects the development and function of self‐specific CD 8+ T cells and regulatory CD 4+ T cells
Twu, Y., & Teh, H. (2013) · Immunology · doi:10.1111/imm.12205 · Cited by 8
Towards Effective Immunotherapy for Lung Cancer: Simultaneous Targeting of Tumor-Initiating Cells and Immune Pathways in the Tumor Microenvironment
Dubinett, S. M., & Sharma, S. P. (2009) · Immunotherapy · doi:10.2217/imt.09.56 · Cited by 8
Targeted Therapy in Melanoma
Davies, M. A., Patel, S., & Kim, K. B. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-424-1_9 · Cited by 8
Multiphoton Imaging of Cytotoxic T Lymphocyte-Mediated Antitumor Immune Responses
Boissonnas, A., Scholer‐Dahirel, A., Fetler, L., & Amigorena, S. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-93864-4_11 · Cited by 8
CD4+CD25+regulatory T cells: a therapeutic target for liver diseases
Zheng, M., Gu, D.-N., Braddock, M., Leishman, A. J., Jin, C., Wen, J., Gong, Y., & Chen, Y. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.3.313 · Cited by 8
Tumor-Localized Ligation of CD3 and CD28 with Systemic Regulatory T-Cell Depletion Induces Potent Innate and Adaptive Antitumor Responses
Lee, C.-H., Chiang, Y., Chang, S., Chong, C.-L., Cheng, B.-M., & Roffler, S. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2311 · Cited by 8
Large intestine intraepithelial lymphocytes from Apc+/+ and Apc+/Min mice and their modulation by indigestible carbohydrates: the IL-15/IL-15R? complex and CD4+CD25+ T cells are the main targets
Forest, V. F., Pierre, F., Bassonga, E., Méflah, K., & Ménanteau, J. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0543-7 · Cited by 8
CD36 as a Therapeutic Target in Tumor Microenvironment and Lipid Metabolism
Li, J., Chen, J., Yang, G., Zhang, S., Li, P., & Ye, L. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206353634241111113338 · Cited by 7
Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
Jeter, J., Cranmer, L. D., & Hersh, E. M. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7245 · Cited by 7
Endogenous CCL21-Ser deficiency reduces B16–F10 melanoma growth by enhanced antitumor immunity
Fujie, R., Kurowarabe, K., Yamada, Y., Fujiwara, K., Nakatani, H., Tsutsumi, K., Hayashi, R., Kawahata, H., Miyamoto, M., Ozawa, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19215 · Cited by 7
Influence of tumors on protective anti-tumor immunity and the effects of irradiation
Foulds, G. A., Radons, J., Kreuzer, M., Multhoff, G., & Pockley, A. G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00014 · Cited by 7
Disruption of T cell regulatory pathways is necessary for immunotherapeutic cure of T cell acute lymphoblastic leukemia in mice.
Susana Fiorentino, G., Chopin, M., Dastot, H., Boissel, N., Reboul, M., Legrès, L., Janin, A., Aplan, P. D., Sigaux, F., & Régnault, A. (2005) · PubMed · Cited by 7
Adjuvant effect of docetaxel on HPV16 L2E6E7 fusion protein vaccine in a mouse model
Su, X., Xu, W., Guan, R., Wang, Y., Wu, J., Zhai, L., Chen, G., & Hu, S. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.005 · Cited by 7
Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET
Hartimath, S., Draghiciu, O., Daemen, T., Nijman, H. W., van Waarde, A., Dierckx, R., & de Vries, E. F. J. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01447-x · Cited by 7
The effects of antibody treatment on regulatory CD4+CD25+ T cells
Yi, H., Zhang, J., & Zhao, Y. L. (2008) · Transplant Immunology · doi:10.1016/j.trim.2007.12.001 · Cited by 7
CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion
Pedersen, A. E., & Ronchese, F. (2007) · Journal of Immune Based Therapies and Vaccines · doi:10.1186/1476-8518-5-9 · Cited by 7
The Many Sounds of T Lymphocyte Silence
Melero, I., Arina, A., & Chen, L. (2005) · Immunologic Research · doi:10.1385/ir:33:2:135 · Cited by 7
Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma
Rovers, S., Audenaerde, J. R. M. V., Verloy, R., Waele, J. D., Brants, L., Hermans, C., Lau, H. W., Merlin, C., Ribas, M. M., Ponsaerts, P., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2512104 · Cited by 6
Mafosfamide Boosts GMI-HBVac against HBV via Treg Depletion in HBV-Infected Mice
Lin, Q., Zhong, Y., & Wang, B. (2023) · Vaccines · doi:10.3390/vaccines11061026 · Cited by 6
Multiple sclerosis and cancer: Navigating a dual diagnosis
Nesbitt, C., van der Walt, A., Butzkueven, H., Devitt, B. A., & Jokubaitis, V. (2024) · Multiple Sclerosis Journal · doi:10.1177/13524585241274523 · Cited by 8
Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints
Dai, Y., Dong, C., Wang, Z., Zhou, Y., Wang, Y., Hao, Y., Chen, P., Liang, C., & Li, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1482291 · Cited by 6
IL‐23 gene therapy for mouse bladder tumour cell lines
Kuramoto, T., Fujii, R., Nagai, H., Belladonna, M. L., Yoshimoto, T., Kohjimoto, Y., Inagaki, T., & Hara, I. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.10025.x · Cited by 6
Combined Cancer Immunotherapy Against Aurora Kinase A
Kaštánková, I., Poláková, I., Dušková, M., & Šmahel, M. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000120 · Cited by 6
Current Immunotherapeutic Strategies in Malignant Melanoma
Agostino, N. M., Ali, A., Nair, S., & Mosca, P. J. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.010 · Cited by 6
Signaling in T cells – is anything the m(a)TOR with the picture(s)?
Boothby, M. R. (2016) · F1000Research · doi:10.12688/f1000research.7027.1 · Cited by 6
Tumor Immunology and Cancer Vaccines
Jensen, S. M., & Fox, B. A. (2005) · Cancer treatment and research · doi:10.1007/0-387-27545-2_13 · Cited by 6
Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile
Somer, L. D., Fevery, S., Bullens, D. M. A., Rutgeerts, O., Lenaerts, C., Mathieu, C., Boon, L., Kasran, A., Waer, M., & Billiau, A. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.06.005 · Cited by 6
Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Dunne, P. J., & Fletcher, J. M. (2010) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/187221310793564182 · Cited by 6

Authors: Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M.
Affiliations: Leiden University Medical Center (NL)
aDepartment of Immunohematology and Blood Transfusion, Tumor Immunology Lab, E3-Q, Leiden University Medical Center, 2300 RC Leiden, Netherlands
The Netherlands Cancer Institute (NL)
University of California, Berkeley (US)
ORCID: Schumacher, Ton N.M.
Wildenberg, Manon E.
Allison, James P.
Offringa, Rienk
Melief, Cornelis J.M.
Venue: The Journal of Experimental Medicine
Publisher: Rockefeller University Press
Published: 2001-09-17
Volume: 194
Issue: 6
Pages: 823-832
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.194.6.823
PMC: PMC2195955
OpenAlex: W2148911309
Cited by: 1,008
References: 44
Citations by year: 2026: 3 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 18 · 2019: 11 · 2018: 12 · 2017: 25 · 2016: 22 · 2015: 36 · 2014: 26 · 2013: 48 · 2012: 41
FWCI: 13.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: cc-by-nc-sa
Locations: The Journal of Experimental Medicine (publishedVersion)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4 blockade, CD25+ regulatory T cells, Treg depletion, antitumor immunity, B16 melanoma, CD8+ T cells, tyrosinase-related protein 2, immune regulation, tumor rejection
MeSH terms: Abatacept, Animals, Antibodies, Monoclonal, Antigens, Differentiation, Antigens, Neoplasm, Female, Immunotherapy, Lymphocyte Depletion, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Nude, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Receptors, Interleukin-2, Biomarkers, CD4-Positive T-Lymphocytes, Antigens, CD, Immunoconjugates, Intramolecular Oxidoreductases, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks